Anvesana

Anvesana is developing therapeutics that increase the expression of specific proteins in order to treat disease. Insufficient protein production is the root cause of many rare genetic disorders and can exacerbate symptoms in larger more genetically complex diseases. Our core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl, cofounder of Alnylam Pharmaceuticals. Our platform queries mRNA sequence data to identify targetable regions for up-regulating gene expression using anti-sense oligonucleotides.